Philippe Camus, M.D.

Dijon, France

Back to drug

The Drug-Induced Respiratory Disease Website

VI.a

Cardiomyopathy (acute, subacute, chronic)

Can be acute or subacute in onset. Severity is from the asymptomatic/subclinical state to overt heart failure. May cause acute or chronic left ventricular dysfunction, congestive heart failure (XIIIa) or cardiogenic pulmonary edema (IId). In some cases, will improve with drug stoppage

Publications

Thoi F, Scherer DJ, Kaye DM, Sanders P, Stokes MB

Methamphetamine-Associated Cardiomyopathy: Addressing the Clinical Challenges.

Heart, lung & circulation 2022 Feb 10;; — 2022 Feb 10

Schürer S, Klingel K, Sandri M, Majunke N, Besler C, Kandolf R, Lurz P, Luck M, Hertel P, Schuler G, Linke A, Mangner N

Clinical Characteristics, Histopathological Features, and Clinical Outcome of Methamphetamine-Associated Cardiomyopathy.

JACC. Heart failure 2017 06;5;435-445 — 2017 06 — 435-445

Karch SB

The unique histology of methamphetamine cardiomyopathy: a case report.

Forensic science international 2011 Oct 10;212;e1-4 — 2011 Oct 10 — e1-4

Kaye S, Darke S, Duflou J, McKetin R

Methamphetamine-related fatalities in Australia: demographics, circumstances, toxicology and major organ pathology.

Addiction (Abingdon, England) 2008 Aug;103;1353-60 — 2008 Aug — 1353-60

Yeo KK, Wijetunga M, Ito H, Efird JT, Tay K, Seto TB, Alimineti K, Kimata C, Schatz IJ

The association of methamphetamine use and cardiomyopathy in young patients.

The American journal of medicine 2007 Feb;120;165-71 — 2007 Feb — 165-71

Hong R, Matsuyama E, Nur K

Cardiomyopathy associated with the smoking of crystal methamphetamine.

JAMA 1991 Mar 06;265;1152-4 — 1991 Mar 06 — 1152-4